Kenvue Inc. Reports Mixed Q4 Results Amid Strong Stock Performance
Summit, New Jersey-based Kenvue Inc. (KVUE) is a consumer health company known for its diverse range of personal care, health, and wellness products. With a market cap of $46 billion, Kenvue’s brand portfolio includes well-recognized names like Tylenol, Listerine, Neutrogena, Aveeno, Band-Aid, and Zyrtec.
Stock Performance Overview
Kenvue has significantly outperformed the broader market over the past 52 weeks. Shares of KVUE have climbed 27.1%, while the S&P 500 Index ($SPX) has increased by 11.7%. On a year-to-date basis, KVUE is up 12.2%, contrasting sharply with SPX’s 4.7% decline.
Comparison with Consumer Staples Sector
When compared to the Vanguard Consumer Staples Index Fund ETF (VDC), which rose 9.7% over the past year and 3.6% year to date, KVUE’s performance becomes even more pronounced.
Q4 Earnings and Projections
On February 6, Kenvue’s shares fell by 4.5% following the release of its Q4 earnings. The company reported revenue of $3.7 billion, a slight decrease from the previous year, and 2.9% below expectations. This shortfall was largely attributed to a drop in Essential Health sales, particularly in the pediatric pain segment, as well as challenges in the Asia-Pacific markets.
When examining earnings, adjusted EPS for the quarter was $0.26, representing a 16.1% decrease year-over-year, although it was in line with analysts’ forecasts. The decline can be linked to weaker adjusted operating income across all reportable segments.
Future Guidance
Looking ahead to fiscal 2025, which ends in December, Kenvue anticipates net sales growth of between -1% and +1%, while expecting adjusted EPS growth of up to 2%. Analysts project that KVUE’s EPS will remain flat year-over-year at $1.14. Notably, the company has met or exceeded consensus estimates in the past four quarters.
Analyst Consensus and Ratings
Among the 16 analysts covering Kenvue, the consensus rating is a “Moderate Buy,” comprising six “Strong Buy” and ten “Hold” ratings. This configuration has remained largely stable over the last three months.
Price Targets
On April 14, Citigroup Inc. (C) maintained a “Neutral” rating on KVUE and increased its price target to $22. The mean price target of $23.97 offers only slight upside from current levels, but the highest target of $29 indicates potential for a 21% rise.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
